z-logo
open-access-imgOpen Access
Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment
Author(s) -
Giuliana Cássia Morrone Taromaru,
Vilmar Marques de Oliveira,
Maria Antonieta Longo Galvão Silva,
Wagner Ricardo Montor,
Fábio Bagnoli,
José Francisco Rinaldi,
Tsutomu Aoki
Publication year - 2011
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2011.532
Subject(s) - ductal carcinoma , tissue microarray , oncogene , breast cancer , medicine , cancer , molecular medicine , ki 67 , carcinogenesis , oncology , cyclooxygenase , immunohistochemistry , cell cycle , insulin like growth factor , growth factor , cancer research , biology , receptor , enzyme , biochemistry
The objective of this study was to evaluate the correlation between cyclooxygenase-2 (COX-2) and markers of cell proliferation and apoptosis, including, Bcl-2, Bax, Ki-67 and the type I insulin-like growth factor (IGF) receptor (IGF1-R) in ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC), present in the same surgical specimen. A total of 110 cases were evaluated using tissue microarrays. Cases were classified in scores from 0 to 3 according to pre-defined methods. The results showed that the positivity rates were COX-2 in 87% of cases in DCIS and IDC; Bcl-2 in 55% of cases in DCIS and IDC; Bax in 23% of cases in IDC and 19% in DCIS, IGF-1 in 24% of cases in DCIS and IDC; and Ki-67 in 81% of cases in DCIS and IDC. We also observed a positive correlation between the expression of COX-2 and IGF1-R (p=0.045). Our results demonstrate a positive correlation between the expression of COX-2 and IGF1-R in DCIS and IDC, demonstrating that they are involved in breast cancer carcinogenesis. Further studies are required to prove the effectiveness of COX-2 and IGF1-R inhibitors for the prevention and treatment of breast cancer, as well as to explain their mechanism of action.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here